Guérin Louis-Philippe, Larouche Danielle, Morcos Mohib W, Faucher Anne, Auger François A, Knoppers Bartha M, Kyrillos Ralph, Bazin Richard, Germain Lucie
Centre de Recherche en Organogénèse Expérimentale de l'Université Laval/LOEX, Quebec, QC G1J 1Z4, Canada.
Centre de Recherche du CHU de Québec-Université Laval, Quebec, QC G1J 1Z4, Canada.
Biomedicines. 2022 Aug 12;10(8):1958. doi: 10.3390/biomedicines10081958.
Damage to limbal epithelial stem cells can lead to limbal stem cell deficiency (LSCD). Current autologous treatment procedures for unilateral LSCD bear a significant risk of inducing LSCD in the donor eye. This complication can be avoided by grafting a stem cell containing cultured autologous corneal epithelium (CACE). The primary objective of this study was to demonstrate the safety of CACE grafted on eyes with LSCD. The secondary objective was to assess the efficacy of a CACE graft in restoring a self-renewing corneal surface with adequate anatomic structures, as well as improving the best corrected visual acuity (BCVA). Fifteen patients were grafted with a CACE on a fibrin gel produced from a 3 mm limbal biopsy harvested from the donor eye. Data were collected at baseline and after grafting. Follow-ups from 1 to 5 years were conducted. No major adverse events related to the CACE graft were observed. For every visit, an anatomic score based on corneal opacity as well as central vascularization and a functional score based on BCVA were determined. Safety was demonstrated by the low occurrence of complications. Anatomical (93%) and functional (47%) results are promising for improving vision in LSCD patients. Combined functional success and partial success rates with inclusion of BCVA were 53% [CI95: 27-79%] one year after CACE grafting. At the last follow-up, 87% [CI95: 60-98%] of the patients had attained corneal clarity. The outcomes demonstrate the safety of our technique and are promising regarding the efficacy of CACE in these patients.
角膜缘上皮干细胞损伤可导致角膜缘干细胞缺乏(LSCD)。目前针对单侧LSCD的自体治疗方法存在供体眼诱导LSCD的重大风险。通过移植含有培养的自体角膜上皮(CACE)的干细胞可以避免这种并发症。本研究的主要目的是证明CACE移植到患有LSCD的眼睛上的安全性。次要目的是评估CACE移植在恢复具有适当解剖结构的自我更新角膜表面以及提高最佳矫正视力(BCVA)方面的疗效。15名患者接受了CACE移植,该CACE移植于从供体眼采集的3mm角膜缘活检产生的纤维蛋白凝胶上。在基线和移植后收集数据。进行了1至5年的随访。未观察到与CACE移植相关的重大不良事件。每次随访时,确定基于角膜混浊以及中央血管化的解剖学评分和基于BCVA的功能评分。并发症发生率低证明了安全性。解剖学(93%)和功能(47%)结果对于改善LSCD患者的视力很有前景。CACE移植一年后,结合功能成功和部分成功率并纳入BCVA为53%[CI95:27 - 79%]。在最后一次随访时,87%[CI95:60 - 98%]的患者角膜达到清晰。结果证明了我们技术的安全性,并且在这些患者中CACE的疗效很有前景。